Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TYMS | P04818 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13026822 | 0.93 | LMNA (0.67) | LMNASMN1; SMN2TYMSPOLB | |
| 5-Fluorodeoxyuridylate SCHEMBL6107 | 0.91 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL15189164 | 0.91 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL973436 | 0.91 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL17117772 | 0.91 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL21901970 | 0.91 | LMNA (0.71) | LMNASMN1; SMN2TYMS | |
| 5-Fluorodeoxyuridylate SCHEMBL25223991 | 0.89 | LMNA (0.69) | LMNASMN1; SMN2TYMS | |
| SCHEMBL19389362 | 0.89 | LMNA (0.68) | LMNASMN1; SMN2TYMSPOLB | |
| SCHEMBL13381629 | 0.89 | LMNA (0.68) | LMNASMN1; SMN2TYMSPOLB | |
| SCHEMBL5491971 | 0.88 | LMNA (0.67) | LMNASMN1; SMN2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365604-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2014-12-18 | — | — | US | disclosed |
| US-8741858-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS | 2014-06-03 | — | — | US | disclosed |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371168-A1 | OLIGOMER-NUCLEOSIDE PHOSPHATE CONJUGATES | ENTPD5, SLC29A2, SLC29A1 | LMNA 4542/4885SMN1; SMN2 1446/4885TYMS 94/4885 |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | ENTPD5, SLC29A2, SLC29A1 | LMNA 4539/4885SMN1; SMN2 1414/4885TYMS 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.